ADOCIA : Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions

PRESS RELEASE

Lyon, June 18th, 2024

ADOCIA Announces Three Presentations at the

American Diabetes Association 84th Scientific

Sessions

• Exclusive non-clinical data have been selected for presentations at ADA on three of Adocia's innovative programs:

1. AdoShell®, aimed as a curative treatment for people with Type 1 Diabetes by delivering human islets or iPSCs1, is progressing towards a First-In-Human trial

1. AdOral® is an oral delivery technology, that could improve bioavailability of semaglutide over Rybelsus®, and applicable to a wide range of therapeutic peptides

1. AdoGel® could ensure a sustained release of semaglutide with a once monthly injection, offering an alternative to today's once weekly injection

6:00 pm CEST - Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, is pleased to announce that exclusive data from three of Adocia's innovative technology platforms have been selected for poster presentations at the upcoming American Diabetes Association's (ADA) 84th Scientific Sessions to be held June 21-24, 2024, in Orlando, Florida.

The annual meeting of the ADA is the largest worldwide scientific meeting for clinicians and researchers in diabetes, obesity and metabolic disorders.

The abstracts are published online on the journal Diabetes®websiteand the ePoster presentations will be available to conference attendees from Friday, June 21, 2024. Posters will be displayed in the Poster Hall, WestA4-B2.

1 iPSCs: induced pluripotent stem cells

• AdoShell®, a non-fibrotic encapsulation system for human islets transplantation shows promising results for clinical application as a cure for people with Type 1 Diabetes
  Xavier Gaume, Romain Besnard, Julie Brun, Nathalie Leclerc, Camille Gautier, Ouardane Jouannot, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Karim Bouzakri (CEED, Strasbourg, France), Olivier Soula
  o Presentation 1504-P: Saturday, June 22, 12:30 pm-1:30 pm (ET)
  AdoShell® is an easily implantable and fully retrievable scaffold for islet transplantation aiming to cure diabetes by cell therapy without requiring immunosuppression. It is based on a permselective hydrogel film allowing insulin diffusion while preventing immune cell invasion. Allogenic transplant of rat islets in immunocompetent diabetic rats has already demonstrated encapsulated islets survival, insulin secretion, and glycemic regulation.
  Compatibility with human islets, local tolerance, and scalability to deliver a therapeutic dose were studied to meet requirements for a first in human. Findings of these studies demonstrate that AdoShell® Islets is suitable for clinical evaluation.
• AdOral®, a versatile platform for improved oral peptide absorption
  Gregory Blache, Anne-Lise Gaffuri, Martin Gaudier, Sana Hakim, Audrey Maréchal, Ulysse Naessens, Romain Noël, Olivier Soula
  o Presentation 1677-P: Monday, June 24, 12:30 pm - 01:30 pm (ET)
  AdOral® is an oral delivery platform based on non-specific Mechanism of Action (MoA) via intestine paracellular passage leading to improved absorption. AdOral®'s MoA and its permeation effect were evaluated in vitro and in vivo on several peptides, including semaglutide, and compared to SNAC (the technology used in Rybelsus®). AdOral® is a versatile and performant platform that could lead to oral formulations for a wide range of therapeutic peptides.
• Development of a once-a-month formulation of Semaglutide from an innovative injectable and biodegradable hydrogel
  Olivier Soula, Claire Mégret, Romain Besnard, Audrey Marechal, Sana Hakim, Jenny Erales, Ulysse Naessens, Maud Fumex, Martin Gaudier, Emmanuel Dauty
  o Presentation 1674-P: Monday, June 24, 12:30 pm - 1:30 pm (ET)
  AdoGel® is an injectable hydrogel technology consisting of cross-linked degradable polymers that allows sustained release of soluble peptides over 1 to 3 months duration. An AdoGel® formulation of semaglutide was tested in rats. Results showed that a sustained release of semaglutide over one month is achievable and could be a real benefit for patient compliance by limiting the injection frequencies, reducing side effects and improving efficacy.

Note: all information contained in the submitted abstract should be considered preliminary and subject to change until the study data and observations are fully presented at the ADA 84th Scientific Sessions and is subject to embargo until June 21, 2024, at 6:30 am ET.

2

About the American Diabetes Association Scientific Sessions

The American Diabetes Association's Scientific Sessionsis the world's largest diabetes meeting, convening more than 11,000 leading physicians, scientists, researchers and health care professionals from around the globe. The meeting features the latest scientific findings in diabetes, including more than 200 sessions and 2,000 original research presentations.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Contact

Adocia	Ulysse Communication
Olivier Soula	Adocia Press & Investor Relations
CEO	Bruno Arabian
[e-mail]	Nicolas Entz
[phone]	[e-mail]
www.adocia.com	+ 33 (0)6 87 88 47 26

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2024, available at www.adocia.com.Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and

development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short- term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

3